Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other financing activities (2016 - 2025)

Lineage Cell Therapeutics' Other financing activities history spans 15 years, with the latest figure at $1000.0 for Q4 2025.

  • For Q4 2025, Other financing activities changed N/A year-over-year to $1000.0; the TTM value through Dec 2025 reached $16000.0, down 30.43%, while the annual FY2025 figure was $16000.0, 30.43% down from the prior year.
  • Other financing activities reached $1000.0 in Q4 2025 per LCTX's latest filing, down from $15000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.3 million in Q2 2023 to a low of $1000.0 in Q4 2025.
  • Average Other financing activities over 5 years is $677357.1, with a median of $918000.0 recorded in 2021.
  • Peak YoY movement for Other financing activities: skyrocketed 128.34% in 2021, then tumbled 98.8% in 2022.
  • A 5-year view of Other financing activities shows it stood at $917000.0 in 2021, then crashed by 98.8% to $11000.0 in 2022, then surged by 11436.36% to $1.3 million in 2023, then crashed by 98.19% to $23000.0 in 2024, then plummeted by 95.65% to $1000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Other financing activities are $1000.0 (Q4 2025), $15000.0 (Q1 2025), and $23000.0 (Q1 2024).